An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Thomas Dahl
- Phone Number: +1 617-818-2735
- Email: tadahl@outlook.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Experienced at least 1 prior episode of transient insomnia meeting all of the following criteria: difficulty falling asleep or staying asleep; next day impairment or distress associated with the disturbed sleep; frequency of 1 to 7 nights per week; duration of less than 1 month or more than 1 month of intermittent episodes.
- Routinely spends 6.5 - 9.5 hours in bed each night, with bed time varying no more than 2 hours over a week.
- Body Mass Index (BMI) between 19 and 32 kg/m2.
- Good general health, as determined by a thorough medical, sleep and psychiatric history review, brief physical examination including vital sign measurements, and an assessment of screening laboratory test results.
- Agrees, for the duration of the study, to take only study drug to address difficulty falling asleep or staying asleep, and to not drink alcohol within 2 hours of expected bedtime.
Exclusion Criteria:
- Females who are pregnant, breast-feeding, or planning a pregnancy during the study period.
- Clinically significant medical disorder or currently unstable medical condition that, in the opinion of the investigator, would confound the results of the study.
- Abnormal laboratory value at screening, judged clinically significant by the investigator.
- History or current evidence of severe hepatic (liver) impairment.
- Clinically significant psychiatric illness, or the history or presence of a major psychiatric illness in the past year.
- Has a significant risk (in the opinion of the investigator) for suicidal behavior during the course of participation in the study or a) At screening: the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to a 6-month period prior to screening; or b) At screening: the subject has had one or more suicidal attempts within a 2-year period prior to screening; or c) At the baseline visit: the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to screening; or d) The subject is considered to be an imminent danger to self or others.
- Has a history of chronic insomnia or other sleep disorders, such as sleep apnea, narcolepsy, parasomnia, restless leg syndrome, or circadian rhythm disorder.
- Has used medications to aid sleep on most nights during the past 2 months.
- Has a history of night work or shift work within the month prior to screening or a need to participate in night work or shift work during the study.
- Has a history of alcohol or substance use disorder within the year prior to screening, or current evidence of alcohol or substance use disorder as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 5th Edition.
- Self-report of a usual consumption of more than 14 units of alcohol per week: 1 unit of alcohol is equivalent to 12 ounces of beer, 4 ounces of wine, or 1 ounce of liquor.
- Has a history of routinely smoking during sleep period.
- Has discontinued smoking or participated in a smoking cessation program within 28 days of screening, or plans to discontinue smoking during the study.
- Has used within 2 weeks or 5 half-lives (whichever is longer) prior to screening of any medication that affects sleep-wake function.
- Has a positive urine drug screen at the screening visit.
- Has a history of allergy or known sensitivity, hypersensitivity, or adverse reaction to diphenhydramine, zolpidem, lorazepam, or related compounds.
- Has had treatment with any other investigational drug within 28 days or 5 half-lives (whichever is longer) prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental (SM-1)
Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
|
SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
|
|
Placebo Comparator: Placebo
Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
|
Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Total Sleep Time
Time Frame: 7 nights
|
Total time spent sleeping each night as reported by the subject
|
7 nights
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pattern of use
Time Frame: 3 months
|
Subject reported total number of uses and consecutive nights of use
|
3 months
|
|
Safety Adverse Events
Time Frame: Through study completion, 17 weeks
|
Adverse Events
|
Through study completion, 17 weeks
|
|
Safety Residual Effects
Time Frame: Through study completion, 17 weeks
|
Subject reported answer to the Question, "How alert or sleepy do you feel this morning?"
Subjects will rate their alertness on a scale from 0 to 5, with 0 being extremely sleepy and 5 being extremely alert
|
Through study completion, 17 weeks
|
|
Safety Rebound Insomnia
Time Frame: Through study completion, 17 weeks
|
Total time spent sleeping each night as reported by the subject on night after taking drug or night after not taking drug
|
Through study completion, 17 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SM-A-06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transient Insomnia
-
NCT00594022CompletedInsomnia | Sleeplessness | Transient Insomnia
-
NCT05253417CompletedInsomnia | Sleep Disturbance | Insomnia Type; Sleep Disorder | Insomnia, Transient | Insomnia Due to Anxiety and Fear | Insomnia Due to Other Mental Disorder
-
NCT00666939Completed
-
NCT00666575Completed
-
NCT00666770Completed
-
NCT00674752CompletedTransient Insomnia
-
NCT00667108Completed
-
NCT00659100Completed
-
NCT03331042Completed
-
NCT01779830CompletedTransient Insomnia
Clinical Trials on SM-1
-
NCT06409195Recruiting
-
NCT05292391Completed
-
NCT03553979UnknownSmoking | Smoking Cessation | Stress | Stress, Psychological | Health Behavior | Smoking, Tobacco | Smoking, Cigarette
-
NCT05136144Active, not recruiting
-
NCT03539978Completed
-
NCT04694261CompletedAnxiety | Resilience | Perinatal Depression | Marital Conflict